Recent developments in bacterial conjugate vaccines

被引:52
作者
Goldblatt, D
机构
[1] Inst Child Hlth, Immunobiol Unit, London WC1N 1EH, England
[2] Great Ormond St Hosp Sick Children, London WC1N 1EH, England
关键词
D O I
10.1099/00222615-47-7-563
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Study of the epidemiology of childhood infection reveals that the brunt of disease for a number of invasive bacterial infections is borne by children under the age of 4 years. Haemophilus influenzae type b (Hib), Neisseria meningitidis and Streptococcus pneumoniae, the three most important causes of childhood meningitis, illustrate this phenomenon, which is caused by the inability of infants and young children to mount antibodies to the carbohydrates that form a capsule surrounding these organisms. Carbohydrates are traditionally viewed as T-independent antigens with a number of unique and important immunological properties that are not encountered when inducing an immune response to proteins. These properties include no overt requirement for the presence of T cells to induce an immune response, dominance of IgM, failure to induce memory following immunisation, an absence of affinity maturation following immunisation, and poor immunogenicity in infants, the elderly and the immunocompromised. These properties of carbohydrates have precluded the use of pure carbohydrate vaccines in those patients most at risk. Conjugate vaccine technology, where a carbohydrate antigen is coupled chemically to a protein carrier, has overcome the limitations of carbohydrates as vaccine antigens by rendering the carbohydrate moiety of such vaccines immunogenic, even in the very young. The dramatic success of the Hib conjugate vaccines, the first conjugates licensed clinically for human use, in reducing the incidence of invasive Hib disease has demonstrated the potential value of such conjugate vaccines. Similar technology is, therefore, being applied to a number of other vaccines in development, including N. meningitidis (groups A and C) and S. pneumoniae vaccines. The large number of pneumococcal carbohydrate serotypes that require inclusion in a vaccine makes this conjugate formulation far more complicated than that for Hib, and it is likely that the dramatic success of the Hib conjugate vaccines will be more difficult to repeat for the pneumococcus.
引用
收藏
页码:563 / 567
页数:5
相关论文
共 41 条
[1]   Pentavalent pneumococcal oligosaccharide conjugate vaccine PncCRM is well-tolerated and able to induce an antibody response in infants [J].
Ahman, H ;
Kayhty, H ;
Tamminen, P ;
Vuorela, A ;
Malinoski, F ;
Eskola, J .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1996, 15 (02) :134-139
[2]   IGG1, IGG2 AND IGM RESPONSES TO 2 HAEMOPHILUS-INFLUENZAE TYPE-B CONJUGATE VACCINES IN YOUNG INFANTS [J].
AMBROSINO, DM ;
SOOD, SK ;
LEE, MC ;
CHEN, D ;
COLLARD, HR ;
BOLON, DL ;
JOHNSON, C ;
DAUM, RS .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1992, 11 (10) :855-859
[3]   Immunogenicity of heptavalent pneumococcal conjugate vaccine in infants [J].
Anderson, EL ;
Kennedy, DJ ;
Geldmacher, KM ;
Donnelly, J ;
Mendelman, PM .
JOURNAL OF PEDIATRICS, 1996, 128 (05) :649-653
[4]   Chemo-immunological studies on conjugated carbohydrate-proteins II. Immunological specificity of synthetic sugar-protein antigens [J].
Avery, OT ;
Goebel, WF .
JOURNAL OF EXPERIMENTAL MEDICINE, 1929, 50 (04) :533-550
[5]   T-CELL REGULATION OF THE ANTIBODY-RESPONSE TO BACTERIAL POLYSACCHARIDE ANTIGENS - AN EXAMINATION OF SOME GENERAL-CHARACTERISTICS AND THEIR IMPLICATIONS [J].
BAKER, PJ .
JOURNAL OF INFECTIOUS DISEASES, 1992, 165 :S44-S48
[6]   OPPOSITE EFFECTS OF ACTIVELY AND PASSIVELY ACQUIRED-IMMUNITY TO THE CARRIER ON RESPONSES OF HUMAN INFANTS TO A HAEMOPHILUS-INFLUENZAE TYPE-B CONJUGATE VACCINE [J].
BARINGTON, T ;
GYHRS, A ;
KRISTENSEN, K ;
HEILMANN, C .
INFECTION AND IMMUNITY, 1994, 62 (01) :9-14
[7]   Vaccine failures after primary immunisation with Haemophilus influenzae type-b conjugate vaccine without booster [J].
Booy, R ;
Heath, PT ;
Slack, MPE ;
Begg, N ;
Moxon, ER .
LANCET, 1997, 349 (9060) :1197-1202
[8]   Reduction of nasopharyngeal carriage of pneumococci during the second year of life by a heptavalent conjugate pneumococcal vaccine [J].
Dagan, R ;
Melamed, R ;
Muallem, M ;
Piglansky, L ;
Greenberg, D ;
Abramson, O ;
Mendelman, PM ;
Bohidar, N ;
Yagupsky, P .
JOURNAL OF INFECTIOUS DISEASES, 1996, 174 (06) :1271-1278
[9]   Randomised trial of the effect of co-administration with acellular pertussis DTP vaccine on immunogenicity of Haemophilus influenzae type b conjugate vaccine [J].
Eskola, J ;
Olander, RM ;
Hovi, T ;
Litmanen, L ;
Peltola, S ;
Kayhty, H .
LANCET, 1996, 348 (9043) :1688-1692
[10]   Conjugate meningococcal serogroup A and C vaccine: Reactogenicity and immunogenicity in United Kingdom infants [J].
Fairley, CK ;
Begg, N ;
Borrow, R ;
Fox, AJ ;
Jones, DM ;
Cartwright, K .
JOURNAL OF INFECTIOUS DISEASES, 1996, 174 (06) :1360-1363